Insurance claim data indicate that nearly 11 percent of women who used mifepristone from 2017 to 2023 experienced serious health complications within 45 days. The issues included hemorrhage, sepsis, cardiac problems, or anaphylaxis. The drug failed in almost 3 percent of cases, requiring surgical follow-up. The FDA initially approved mifepristone for up to seven weeks of pregnancy, but it was extended to 10 weeks under President Obama's administration in 2016. President Biden's administration removed requirements for in-person dispensing and severe side effect reporting in 2023. | 
